| Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF M Vaduganathan, RJ Mentz, BL Claggett, ZM Miao, IJ Kulac, JH Ward, ... European Heart Journal 44 (31), 2982-2993, 2023 | 41 | 2023 |
| Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: a participant-level pooled analysis of DAPA-HF and … AS Desai, PS Jhund, BL Claggett, M Vaduganathan, ZM Miao, T Kondo, ... JAMA cardiology 7 (12), 1227-1234, 2022 | 33 | 2022 |
| Virtual care team guided management of patients with heart failure during hospitalization AS Bhatt, AS Varshney, A Moscone, BL Claggett, ZM Miao, S Chatur, ... Journal of the American College of Cardiology 81 (17), 1680-1693, 2023 | 30* | 2023 |
| Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial M Metra, M Pagnesi, BL Claggett, R Díaz, GM Felker, JJV McMurray, ... European Heart Journal 43 (48), 5006-5016, 2022 | 22 | 2022 |
| Influence of NT-proBNP on efficacy of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction PL Myhre, M Vaduganathan, BL Claggett, ZM Miao, PS Jhund, ... Heart Failure 10 (12), 902-913, 2022 | 22 | 2022 |
| Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial S Chatur, M Vaduganathan, B Claggett, O Vardeny, AS Desai, PS Jhund, ... European heart journal 44 (31), 2930-2943, 2023 | 21 | 2023 |
| Blood pressure and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: DELIVER S Selvaraj, M Vaduganathan, BL Claggett, ZM Miao, JC Fang, O Vardeny, ... Heart Failure 11 (1), 76-89, 2023 | 17 | 2023 |
| Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial SD Solomon, BL Claggett, ZM Miao, R Diaz, GM Felker, JJV McMurray, ... European heart journal 43 (23), 2212-2220, 2022 | 14 | 2022 |
| Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to polypharmacy status A Peikert, P Goyal, M Vaduganathan, BL Claggett, IJ Kulac, ZM Miao, ... Heart Failure 11 (10), 1380-1393, 2023 | 11 | 2023 |
| Cardio-renal-metabolic overlap, outcomes, and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction JW Ostrominski, J Thierer, BL Claggett, ZM Miao, AS Desai, PS Jhund, ... Heart Failure 11 (11), 1491-1503, 2023 | 10 | 2023 |
| Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials AS Bhatt, MN Kosiborod, M Vaduganathan, BL Claggett, ZM Miao, ... European Journal of Heart Failure 25 (7), 981-988, 2023 | 9 | 2023 |
| Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B‐type natriuretic peptide level: insights from the GALACTIC‐HF trial KF Docherty, JJV McMurray, BL Claggett, ZM Miao, KF Adams, ... European Journal of Heart Failure 25 (2), 248-259, 2023 | 9 | 2023 |
| Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial AS Bhatt, MN Kosiborod, BL Claggett, ZM Miao, M Vaduganathan, ... European Journal of Heart Failure 25 (12), 2177-2188, 2023 | 7 | 2023 |
| Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the … S Chatur, JW Cunningham, M Vaduganathan, FR Mc Causland, ... European Journal of Heart Failure 25 (7), 1170-1175, 2023 | 7 | 2023 |
| Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA‐HF S Chatur, T Kondo, BL Claggett, K Docherty, ZM Miao, AS Desai, ... European journal of heart failure 25 (8), 1364-1371, 2023 | 5 | 2023 |
| Dapagliflozin and all-cause hospitalizations in patients with heart failure with preserved ejection fraction M Vaduganathan, BL Claggett, P Jhund, ZM Miao, RA de Boer, CSP Lam, ... Journal of the American College of Cardiology 81 (10), 1004-1006, 2023 | 5 | 2023 |
| Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: The DELIVER Trial JW Ostrominski, M Vaduganathan, S Selvaraj, BL Claggett, ZM Miao, ... Circulation 148 (24), 1945-1957, 2023 | 4 | 2023 |
| Geographic differences in patients with acute myocardial infarction in the PARADISE‐MI trial JH Butt, BL Claggett, ZM Miao, KS Jering, D Sim, P van der Meer, ... European Journal of Heart Failure 25 (8), 1228-1242, 2023 | 4 | 2023 |
| Angiotensin receptor-neprilysin inhibition in patients with STEMI vs NSTEMI DL Mann, J Nicolas, B Claggett, ZM Miao, CB Granger, P Kerkar, L Køber, ... Journal of the American College of Cardiology 83 (9), 904-914, 2024 | 3 | 2024 |
| Tricuspid regurgitation and clinical outcomes in heart failure with reduced ejection fraction M Adamo, M Metra, BL Claggett, ZM Miao, R Diaz, GM Felker, ... Heart Failure 12 (3), 552-563, 2024 | 3 | 2024 |
Brian ClaggettHarvard Medical School在 partners.org 的电子邮件经过验证
Brian ClaggettHarvard Medical School在 partners.org 的电子邮件经过验证
Scott SolomonBrigham and Women's Hospital在 rics.bwh.harvard.edu 的电子邮件经过验证